Table 1. Characteristics of studies included in the meta-analysis.

Variables	SOCCAR (22)			EORTC (23)
	HYPO-RT-C	HYPO-RT-S		HYPO-RT-C	HYPO-RT-S
Patients	70	60		80	78
Age (mean)	61	64		62	64
Female (%)	36	33		26	22
Male (%)	64	67		74	78
Clinical stage III (%)	100	100		94	93
Histology (%)
Adenocarcinoma	26	28		24	32
Squamous cell carcinoma	69	58		40	40
Radiotherapy (Gy)
Total dose (median)	55	55		66	66
Dose/fraction (median)	2.75	2.75		2.75	2.75
Chemotherapy	Cisplatin 20 mg/m2 was given days 1–4 and 16–19. Vinorelbine was 15 mg/m2 given days 1, 6, 15 and 20	Cisplatin 80 mg/m2 IV on day 1 and vinorelbine 25 mg/m2 IV on day 1 and 8 (q 21) for 3–4 cycles		Cisplatin (6 mg/m2) 1–2 hours before each fraction	Gemcitabine (1,250 mg/m2 days 1,8) and Cisplatin (75 mg/m2 day 2)
Follow-up, mouth (median)	35	35		39	39

HYPO-RT, hypofractionated radiotherapy.